Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
NVS earnings call for the period ending December 31, 2022.
Bloomberg's Joe Easton has a rundown of the stocks to keep an eye on today, including pharmaceutical firms Novartis, Novo Nordisk and GSK, Spanish bank BBVA, and Ladbrokes owner Entain. He speaks on Bloomberg Television. Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en